Incidence of Venous Thromboembolism and Cardiovascular Events in Breast Cancer Patients Undergoing Cyclin-dependent Kinase 4/6 Inhibitors: The Breast Cancer Associated Vascular Events During Cyclin-dependent Kinase 4/6 Inhibitors Therapy (BRAVE-Cyclin) Study

计划入组 300 人 · 首次发布于 2025 年 6 月 6 日

Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases

首次发布于 2020 年 10 月 14 日

Fulvestrant With Ribociclib Versus Physician's Choice Treatments Recurred After Completion of Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in HR+, HER2- Metastatic Breast Cancer

计划入组 272 人 · 首次发布于 2025 年 2 月 27 日

Cyclin-dependent kinase inhibitors(Banyu)

Cyclin-dependent kinase inhibitors(Boehringer Ingelheim)

CDK2 targeting program (Monte Rosa Therapeutics)

6'Naps

Belgium

October 6 University

Egypt

Ningbo No.6 Hospital

China

CDK4/6 Inhibitors Plus Endocrine Therapy Improves Survival in HR+/HER2- Advanced Breast Cancer

CDK4/6 Inhibitors Plus Endocrine Therapy Significantly Improve Outcomes in Advanced Breast Cancer

Abemaciclib Shows Promise in ER+/HER2- Advanced Breast Cancer Treatment